Novimmune appoints experienced CFO

In announcing the appointment, Jack Barbut, Chief Executive Officer of Novimmune, commented, "I am very pleased to welcome Andrew to Novimmune. With Novimmune's research and development efforts maturing, our company will benefit significantly from his extensive experience in both the biopharmaceutical industry and the global capital markets."

Dr. Eduard Holdener, Chairman of Novimmune, added, "We are delighted that Novimmune has been able to attract a professional of such high caliber as Andrew. The appointment of such an experienced public company CFO highlights our ambition to rapidly advance Novimmune's corporate and business strategy."

In his ten years at Actelion, a global biopharmaceutical company with a market capitalization exceeding CHF 10 billion, Andrew built and led a global finance function and initiated and executed a number of Capital Markets Transactions. Prior to this appointment, Andrew held a number of senior managerial and financial roles at several organizations in Australia, the UK and the US.

Andrew J. Oakley said, "I am excited to join my new colleagues at Novimmune at this important time in the company's development. I am confident that together, we will continue to create value for our investors, and benefits for patients, by advancing important new medicines either through strategic collaborations or, in the case of orphan indications, on our own."